Pharmacokinetics and pharmacodynamics of biotech drugs: principles and case studies in drug development
Saved in:
| Format: | Book |
|---|---|
| Language: | English |
| Published: |
Weinheim
Wiley-VCH
2006
|
| Subjects: | |
| Online Access: | Inhaltsverzeichnis |
| Physical Description: | XXI, 403 S. Ill., graph. Darst. |
| ISBN: | 9783527314089 3527314083 |
Staff View
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV022446743 | ||
| 003 | DE-604 | ||
| 005 | 20090304 | ||
| 007 | t | ||
| 008 | 070531s2006 ad|| |||| 00||| eng d | ||
| 020 | |a 9783527314089 |c Gb. : EUR 139.00 |9 978-3-527-31408-9 | ||
| 020 | |a 3527314083 |c Gb. : EUR 139.00 |9 3-527-31408-3 | ||
| 035 | |a (OCoLC)427472250 | ||
| 035 | |a (DE-599)BVBBV022446743 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-19 |a DE-20 |a DE-29 |a DE-M49 |a DE-29T | ||
| 050 | 0 | |a RS380 | |
| 082 | 0 | |a 615.19 |2 22 | |
| 084 | |a VX 8550 |0 (DE-625)147830:253 |2 rvk | ||
| 084 | |a CIT 840f |2 stub | ||
| 245 | 1 | 0 | |a Pharmacokinetics and pharmacodynamics of biotech drugs |b principles and case studies in drug development |c ed. by Bernd Meibohm |
| 264 | 1 | |a Weinheim |b Wiley-VCH |c 2006 | |
| 300 | |a XXI, 403 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 650 | 4 | |a Biotecnología farmaceútica | |
| 650 | 4 | |a Desarrollo de drogas | |
| 650 | 4 | |a Drogas - Efectos fisiológicos | |
| 650 | 4 | |a Farmacocinética | |
| 650 | 0 | 7 | |a Arzneimittelentwicklung |0 (DE-588)4143176-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmakodynamik |0 (DE-588)4174134-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmakokinetik |0 (DE-588)4115557-9 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Pharmakokinetik |0 (DE-588)4115557-9 |D s |
| 689 | 0 | 1 | |a Arzneimittelentwicklung |0 (DE-588)4143176-5 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Pharmakodynamik |0 (DE-588)4174134-1 |D s |
| 689 | 1 | 1 | |a Arzneimittelentwicklung |0 (DE-588)4143176-5 |D s |
| 689 | 1 | |C b |5 DE-604 | |
| 700 | 1 | |a Meibohm, Bernd |e Sonstige |0 (DE-588)114901619 |4 oth | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015654691&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-015654691 | ||
Record in the Search Index
| _version_ | 1804136524805046272 |
|---|---|
| adam_text | Contents
Foreword V
Preface VII
List of Contributors XIX
Part I: Introduction
1 The Role of Pharmacokinetics and Pharmacodynamics in the
Development of Biotech Drugs 3
Bernd Meibohm
1.1 Introduction 3
1.2 Biotech Drugs and the Pharmaceutical Industry 4
1.3 Pharmacokinetics and Pharmacodynamics in Drug Development 6
1.4 PK and PK/PD Pitfalls for Biotech Drugs 9
1.5 Regulatory Guidance 10
1.6 Future 10
1.7 References 12
Part II: The Basics
2 Pharmacokinetics of Peptides and Proteins 17
Lisa Tang and Bernd Meibohm
2.1 Introduction 17
2.2 Administration Pathways 18
2.2.1 Administration by Injection or Infusion 18
2.2.2 Inhalational Administration 23
2.2.3 Intranasal Administration 24
2.2.4 Transdermal Administration 25
2.2.5 Peroral Administration 25
2.3 Administration Route and Immunogenicity 27
2.4 Distribution 28
2.5 Elimination 29
2.5.1 Proteolysis 32
2.5.2 Gastrointestinal Elimination 32
2.5.3 Renal Elimination 32
2.5.4 Hepatic Elimination 34
2.5.5 Receptor Mediated Endocytosis 35
2.6 Interspecies Scaling 36
2.7 Conclusions 37
2.8 References 38
3 Pharmacokinetics of Monoclonal Antibodies 45
Katharina Kuester and Charlotte Klofi
3.1 Introduction 45
3.2 The Human Immune System 46
3.2.1 The Cellular Immune Response 47
3.2.2 The Humoral Immune Response 47
3.3 Physiological Antibodies 48
3.3.1 Classes of Antibodies 48
3.3.1.1 Immunoglobulin G 48
3.3.1.2 Immunoglobulins A, D, M, and E 49
3.3.2 Chemical Structure of Antibodies 50
3.4 Therapeut«: Antibodies 52
3.4.1 Therapeutic Polyclonal Antibodies 52
3.4.2 Therapeutic mAbs 53
3.4.2.1 Murine mAbs 53
3.4.2.2 Chimeric mAbs 55
3.4.2.3 Humanized mAbs 55
3.4.2.4 Human mAbs 55
3.4.2.5 Further Species of mAbs 56
3.5 Effector Functions and Modes of Action of Antibodies 58
3.5.1 Biological Effector Functions of mAbs 58
3.5.2 Modes of Action of mAbs 59
3.5.2.1 Antibody Dependent Cellular Cytotoxicity (ADCC) 59
3.5.2.2 Complement Dependent Cytotoxicity 60
3.5.2.3 Blockage of Interaction between (Patho)Physiological Substance
and Antigen 61
3.5.2.4 Conjugated Unlabeled mAbs 61
3.5.2.5 Radioactively Labeled mAbs 61
3.6 Prerequisites for mAb Therapy 62
3.6.1 The Patient 62
3.6.2 The Antibody 63
3.6.3 The Target Cell 63
3.6.4 The Antigen 63
3.7 Issues in the Bioanalysis of Antibodies 64
¦
3.8 Catabolism of Antibodies 65
3.8.1 Proteolytic Degradation 65
3.8.2 Neonatal Fc Receptor (Fc Rn) 65
3.9 Pharmacokinetic Characteristics of mAbs 68
3.9.1 Absorption 68
3.9.2 Distribution 71
3.9.2.1 Transport 71
3.9.2.2 Volume of Distribution 72
3.9.2.3 Types of Binding 74
3.9.3 Elimination 76
3.9.3.1 Clearance 76
3.9.3.2 Proteolysis 76
3.9.3.3 Binding to Antigen 77
3.9.3.4 Binding to Anti Idiotype Antibodies 77
3.9.3.5 Drag Interaction Studies 78
3.9.4 Comparison of Pharmacokinetics of mAbs and Traditional
Small Molecule Drugs 78
3.10 Pharmacokinetic Modeling of mAbs 79
3.10.1 Noncompartmental Pharmacokinetic Analysis 79
3.10.2 Individual Compartmental Pharmacokinetic Analysis 80
3.10.3 Population Pharmacokinetic Analysis 81
3.10.3.1 Structural Submodel 82
3.10.3.2 Statistical Submodel 85
3.10.3.3 Covariate Submodel 85
3.11 Pharmacodynamics of mAbs 86
3.12 Conclusions 90
3.13 References 91
4 Pharmacokinetics and Pharmacodynamics of Antisense
Oligonucleotides 93
Rosie Z. Yu, Richard S. Ceary, and Arthur A. Lev m
4.1 Introduction 93
4.2 Pharmacokinetics 96
4.2.1 Plasma Pharmacokinetics Across Species 97
4.2.2 Tissue Distribution 100
4.2.3 Metabolism 102
4.2.4 Elimination and Excretion 105
4.3 Pharmacodynamics 108
4.3.1 Pharmacological Endpoint: Reduction of Target mRNA
and Protein 109
4.3.2 Pharmacological Endpoint: Downstream Effects 113
4.3.3 Relationship berween ASO Pharmacokinetics and Clinical Outcome 113
4.4 Summary 115
4.5 References 115
5 Pharmacokinetics of Viral and Non Viral Gene Delivery Vectors 121
Martin Meyer, Cururaj Rao, Ke Ren, and Jeffrey Hughes
5.1 General Overviewof Gene Therapy 121
5.2 Anatomical Considerations 122
5.3 Naked DNA 122
5.4 Non Viral Vectors 124
5.4.1 Polymer Based Vectors 126
5.4.1.1 Introduction 126
5.4.1.2 Influence of Charge and Size 127
5.4.1.3 Biodistribution and Gene Expression 128
5.4.2 Lipid Based Vectors 131
5.4.2.1 Introduction 131
5.4.2.2 Influence of Physico Chemical Properties 133
5.4.2.3 Biodistribution and Gene Expression 134
5.5 Viral Vectors 136
5.5.1 rAAV: Properties 136
5.5.2 rAAV Serotype and Biodistribution 138
5.6 Summary 139
5.7 References 139
Part III: Challenges and Opportunities
6 Bioanalytical Methods Used for Pharmacokinetic Evaluations
of Biotech Macromolecule Drugs: Issues, Assay Approaches,
and Limitations 147
Jean W. Lee
6.1 Introduction 147
6.2 Bioanalytical Methods for Macromolecule Drug Analysis: Common
Considerations 148
6.2.1 Sample Integrity and Analyte Stability 148
6.2.2 Surface Adsorption 149
6.2.3 Process of Method Development and Validation of Bioanalytical
Methods for Macromolecule Drug Analysis 150
6.2.4 Reference Standards 151
6.2.5 Drug Compounds that Exist Endogenously 152
6.2.6 Validation Samples, Quality Controls, and Assay Range 353
6.2.7 Protein Binding Problems 153
6.3 The Bioanalytical Method Workhorses 154
6.3.1 Ligand Binding Assays: Immunoassays 157
6.3.1.1 Common Method Approach 157
6.3.1.2 Advantages of Immunoassays 158
6.3.1.3 Issues and Limitations of Immunoassays 158
6.3.2 HPLC ESI MS/MS Methods 162
i.ontents I X
6.3.2.1 Common Method Approach 162
6.3.2.2 AdvantagesofHPLC ESI MS/MSMethods 162
6.3.2.3 Issuesand Limitations of LC ESI MS/MS Methods 262
6.4 Case Studies 267
6.4.1 Development and Validation of an ELISA Method for an Antibody
Drug 167
6.4.2 Development and Validation of a Sandwich Immunoradiometric
Method Using Commercial Kits for a Recombinant Peptide Drug 169
6.4.3 Development and Validation of LC MS/MS Method for a Peptide
Drug 171
6.5 Future Perspectives: Emerging Quantitative Methods 173
6.5.1 Sample Clean Up 173
6.5.2 Innovations in MS Instruments 173
6.5.3 Quantification using Signature Hydrolytic Peptides 174
6.5.4 Advances in Ligand Reagents Design and Production 175
6.6 Conclusions 175
6.7 References 176
7 Limitations of Noncompartmental Pharmacokinetic Analysis
of Biotech Drugs 281
Arthur B. Straughn
7.1 Introduction 181
7.2 The Conceptof Volume of Distribution 282
7.3 Calculation of Vss 283
7.4 Pitfalls in Calculating Vss 285
7.5 Results and Discussion 187
7.6 Conclusions 288
7.7 References 188
8 Bioequivalence of Biologics 289
Jeffrey S. Barrett
8.1 Introduction 289
8.2 Prevailing Opinion: Science, Economics, and Politics 191
8.3 Biologics: Time Course of Immunogenicity 293
8.4 Pharmaceutical Equivalence 296
8.4.1 How Changes in Quality Might Affect Safety and Efficacy 197
8.5 Bioequivalence: Metrics and Methods for Biologics? 298
8.6 Case Study: Low Molecular Weight Heparins 200
8.7 Conclusions 205
8.8 References 206
9 Biopharmaceutical Challenges: Pulmonary Delivery of Proteins
and Peptides 209
Kun Cheng and Ram I. Mahato
9.1 Introduction 209
9.2 Structure and Physiology of the Pulmonary System 211
9.2.1 Airway Epithelium 212
9.2.2 Alveolar Epithelium 214
9.3 Barriers to Pulmonary Absorption of Peptides and Proteins 214
9.4 Strategies for Pulmonary Delivery 215
9.4.1 Intratracheal Instillation 215
9.4.2 Aerosol Inhalation 215
9.4.2.1 Aerosol Deposition Mechanisms 216
9.4.2.2 Devices for Pulmonary Drag Delivery 216
9.5 Experimental Models 220
9.5.1 Isolated Perfused Lung Model 220
9.5.2 Cell Culture Models 220
9.6 Pulmonary Delivery of Peptides and Proteins 221
9.6.1 Mechanisms of Peptide Absorption after Pulmonary Delivery 221
9.6.2 Mechanisms of Protein Absorption after Pulmonary Delivery 222
9.6.3 Pulmonary Delivery of Peptides and Proteins 223
9.6.3.1 Insulin 223
9.6.3.2 Salmon Calcitonin 227
9.6.3.3 Luteinizing Hormone Releasing Hormone (LHRH) Agonists/
Antagonists 229
9.6.3.4 Vasopressin 230
9.6.3.5 Granulocyte Colony Stimulating Factor (G CSF) 231
9.6.3.6 Interferons 232
9.6.3.7 TSH, FSH, and HCG 233
9.6.3.8 Ekstase Inhibitors 233
9.7 Limitations of Aerosol Delivery 234
9.8 Summary 235
9.9 References 235
10 Biopharmaceutical Challenges: Delivery of Oligonucleotides 243
Lloyd C. Tillman and Gregory E. Hardee
10.1 Introduction 243
10.2 ASOs: The Physico Chemical Properties 244
10.3 Local Administration 246
10.3.1 Ocular Delivery 246
10.3.2 Local Gastrointestinal Delivery 247
10.3.2.1 Rectal Dosing 247
10.3.2.2 Oral Dosing 248
10.3.3 Pulmonary Delivery 249
10.3.3.1 Formulation Considerations 251
Contents I )0
10.3.3.2 Deposition and Uptake 251
10.3.4 Delivery to the Brain 253
10.3.5 Topical Delivery 253
10.3.6 Other Local Delivery Approaches 254
10.4 Systemic Delivery 255
10.4.1 Parenteral Routes 255
10.4.1.1 Sustained Release Subcutaneous Formulations 256
10.4.2 Oral Delivery 257
10.4.2.1 Permeability 258
10.4.2.2 Systemic Bioavailability 260
10.5 Conclusions 265
10.6 References 266
11 Custom Tailored Pharmacokinetics and Pharmacodynamics
via Chemical Modifications of Biotech Drugs 271
Francesco M. Veronese and Paolo Caliceti
11.1 Introduction 271
11.2 Polymers Used in Biotechnological Drug PEGylation 272
11.3 Advantages of PEG as Drug Carrier 273
11.4 Chemical Aspects Critical for the Pharmacokinetics of Drug
Conjugates 274
11.5 Insulin 279
11.6 Interferons 282
11.7 Avidin 285
11.8 Non Peptide Drug Conjugation 288
11.8.1 Amphotericin B 289
11.8.2 Camptothecins 290
11.8.3 Cytosine Arabinoside (Ara C) 292
11.9 Concluding Remarks 292
11.10 References 292
12 Exposure Response Relationships for Therapeutic Biologie
Products 295
Mohammad Tabrizi and Lorin K. Roskos
12.1 Introduction 295
12.2 Overview of Pharmacokinetics and Pharmacodynamics 295
12.2.1 Pharmacokinetics 295
12.2.1.1 Absorption 296
12.2.1.2 Distribution 296
12.2.1.3 Elimination 296
12.2.1.4 Immunogenicity 298
12.2.2 Pharmacodynamics 298
12.3 Hormones 300
12.3.1 Insulin 301
12.3.2 Parathyroid Hormone 302
12.4 Cytokines 303
12.4.1 Interleukin 2 305
12.5 Growth Factors 306
12.5.1 Epoetin oc 307
12.6 Soluble Receptors 308
12.6.1 Etanercept 308
12.7 Monoclonal Antibodies (mAbs) 310
12.7.1 Therapeutic Antibodies in Inflammatory Diseases 311
12.7.1.1 Anti TNF a Antibodies 314
12.7.1.2 Efalizumab 316
12.7.1.3 Omalizumab 317
12.7.2 Therapeutic Antibodies in Oncology 317
12.7.2.1 Rituximab 318
12.7.2.2 Bevacizumab 319
12.7.2.3 Trastuzumab 320
12.8 Conclusions 321
12.9 References 321
Part IV: Examples for the Integration of Pharmacokinetic and
Pharmacodynamic Concepts Into the Biotech Drug Development Plan
13 Preclinical and Clinical Drug Development of Tasidotin,
a Depsi Pentapeptide Oncolytic Agent 331
Peter L. Bonate, Larry Arthaud, and Katherme Stephenson
13.1 Introduction 331
13.2 The Dolastatins 331
13.3 Discovery and Preclinical Pharmacokinetics of Tasidotin 333
13.4 Preclinical Pharmacology of Tasidotin and ILX651 C Carboxylate 334
13.5 Toxicology of Tasidotin 334
13.6 Clinical Pharmacology and Studies of Tasidotin in Patients with Solid
Tumors 335
13.7 Clinical Pharmacology of ILX651 C Carboxylate 341
13.8 Exposure Response Relationships 342
13.9 Discussion 343
13.10 Summary 349
13.11 References 349
Contents IXV
14 Clinical Drug Development ofCetuximab, a Monoclonal Antibody 353
Arno Nolting, Floyd E. Fox, and Andreas Kovar
14.1 Introduction 353
14.2 Specific Considerations in Oncologic Drug Development 354
14.3 Introduction to the Clinical Pharmacokinetics ofCetuximab 356
14.4 Early Attempts to Characterize the PK ofCetuximab 356
14.5 PK ofCetuximab Following Poolingof Data Across All Studies 357
14.5.1 Comparison of Single Dose PK Parameters at Various Dose Levels 357
14.5.1.1 Maximum Serum Concentration 357
14.5.1.2 Area Under the Concentration Time Curve 359
14.5.1.3 Clearance 360
14.5.1.4 Elimination Half Life 361
14.5.1.5 Volume of Distribution 361
14.5.2 Drug Metabolism and in vitro Drug Drug Interaction Studies 362
14.5.3 Comparison of Single and Multiple Dose PK at the Approved Dosing
Regimen 362
14.6 Characterization ofCetuximab PK by a Population PK Approach 364
14.7 Drug Drug Interaction Studies 366
14.8 Conclusions 369
14.9 References 370
15 Integration of Pharmacokinetics and Pharmacodynamics Into the Drug
Development of Pegfilgrastim, a Pegylated Protein 373
Bing Bing Yang
15.1 Introduction 373
15.2 Overviewof Filgrastim Pharmacokinetics 374
15.3 The Making of Pegfilgrastim 3 75
15.4 Preclinical Pharmacokinetics and Pharmacodynamics of
Pegfilgrastim 376
15.5 Pharmacokinetic and Pharmacodynamic Modeling 379
15.6 Clinical Pharmacokinetics and Pharmacodynamics of
Pegfilgrastim 381
15.7 Basis for the Fixed Dose Rationale 385
15.8 Clinical Evaluation of the Fixed Dose 389
15.9 Summary 391
15.10 References 391
Subject Index 395
|
| adam_txt |
Contents
Foreword V
Preface VII
List of Contributors XIX
Part I: Introduction
1 The Role of Pharmacokinetics and Pharmacodynamics in the
Development of Biotech Drugs 3
Bernd Meibohm
1.1 Introduction 3
1.2 Biotech Drugs and the Pharmaceutical Industry 4
1.3 Pharmacokinetics and Pharmacodynamics in Drug Development 6
1.4 PK and PK/PD Pitfalls for Biotech Drugs 9
1.5 Regulatory Guidance 10
1.6 Future 10
1.7 References 12
Part II: The Basics
2 Pharmacokinetics of Peptides and Proteins 17
Lisa Tang and Bernd Meibohm
2.1 Introduction 17
2.2 Administration Pathways 18
2.2.1 Administration by Injection or Infusion 18
2.2.2 Inhalational Administration 23
2.2.3 Intranasal Administration 24
2.2.4 Transdermal Administration 25
2.2.5 Peroral Administration 25
2.3 Administration Route and Immunogenicity 27
2.4 Distribution 28
2.5 Elimination 29
2.5.1 Proteolysis 32
2.5.2 Gastrointestinal Elimination 32
2.5.3 Renal Elimination 32
2.5.4 Hepatic Elimination 34
2.5.5 Receptor Mediated Endocytosis 35
2.6 Interspecies Scaling 36
2.7 Conclusions 37
2.8 References 38
3 Pharmacokinetics of Monoclonal Antibodies 45
Katharina Kuester and Charlotte Klofi
3.1 Introduction 45
3.2 The Human Immune System 46
3.2.1 The Cellular Immune Response 47
3.2.2 The Humoral Immune Response 47
3.3 Physiological Antibodies 48
3.3.1 Classes of Antibodies 48
3.3.1.1 Immunoglobulin G 48
3.3.1.2 Immunoglobulins A, D, M, and E 49
3.3.2 Chemical Structure of Antibodies 50
3.4 Therapeut«: Antibodies 52
3.4.1 Therapeutic Polyclonal Antibodies 52
3.4.2 Therapeutic mAbs 53
3.4.2.1 Murine mAbs 53
3.4.2.2 Chimeric mAbs 55
3.4.2.3 Humanized mAbs 55
3.4.2.4 Human mAbs 55
3.4.2.5 Further Species of mAbs 56
3.5 Effector Functions and Modes of Action of Antibodies 58
3.5.1 Biological Effector Functions of mAbs 58
3.5.2 Modes of Action of mAbs 59
3.5.2.1 Antibody Dependent Cellular Cytotoxicity (ADCC) 59
3.5.2.2 Complement Dependent Cytotoxicity 60
3.5.2.3 Blockage of Interaction between (Patho)Physiological Substance
and Antigen 61
3.5.2.4 Conjugated Unlabeled mAbs 61
3.5.2.5 Radioactively Labeled mAbs 61
3.6 Prerequisites for mAb Therapy 62
3.6.1 The Patient 62
3.6.2 The Antibody 63
3.6.3 The Target Cell 63
3.6.4 The Antigen 63
3.7 Issues in the Bioanalysis of Antibodies 64
¦
3.8 Catabolism of Antibodies 65
3.8.1 Proteolytic Degradation 65
3.8.2 Neonatal Fc Receptor (Fc Rn) 65
3.9 Pharmacokinetic Characteristics of mAbs 68
3.9.1 Absorption 68
3.9.2 Distribution 71
3.9.2.1 Transport 71
3.9.2.2 Volume of Distribution 72
3.9.2.3 Types of Binding 74
3.9.3 Elimination 76
3.9.3.1 Clearance 76
3.9.3.2 Proteolysis 76
3.9.3.3 Binding to Antigen 77
3.9.3.4 Binding to Anti Idiotype Antibodies 77
3.9.3.5 Drag Interaction Studies 78
3.9.4 Comparison of Pharmacokinetics of mAbs and Traditional
Small Molecule Drugs 78
3.10 Pharmacokinetic Modeling of mAbs 79
3.10.1 Noncompartmental Pharmacokinetic Analysis 79
3.10.2 Individual Compartmental Pharmacokinetic Analysis 80
3.10.3 Population Pharmacokinetic Analysis 81
3.10.3.1 Structural Submodel 82
3.10.3.2 Statistical Submodel 85
3.10.3.3 Covariate Submodel 85
3.11 Pharmacodynamics of mAbs 86
3.12 Conclusions 90
3.13 References 91
4 Pharmacokinetics and Pharmacodynamics of Antisense
Oligonucleotides 93
Rosie Z. Yu, Richard S. Ceary, and Arthur A. Lev'm
4.1 Introduction 93
4.2 Pharmacokinetics 96
4.2.1 Plasma Pharmacokinetics Across Species 97
4.2.2 Tissue Distribution 100
4.2.3 Metabolism 102
4.2.4 Elimination and Excretion 105
4.3 Pharmacodynamics 108
4.3.1 Pharmacological Endpoint: Reduction of Target mRNA
and Protein 109
4.3.2 Pharmacological Endpoint: Downstream Effects 113
4.3.3 Relationship berween ASO Pharmacokinetics and Clinical Outcome 113
4.4 Summary 115
4.5 References 115
5 Pharmacokinetics of Viral and Non Viral Gene Delivery Vectors 121
Martin Meyer, Cururaj Rao, Ke Ren, and Jeffrey Hughes
5.1 General Overviewof Gene Therapy 121
5.2 Anatomical Considerations 122
5.3 Naked DNA 122
5.4 Non Viral Vectors 124
5.4.1 Polymer Based Vectors 126
5.4.1.1 Introduction 126
5.4.1.2 Influence of Charge and Size 127
5.4.1.3 Biodistribution and Gene Expression 128
5.4.2 Lipid Based Vectors 131
5.4.2.1 Introduction 131
5.4.2.2 Influence of Physico Chemical Properties 133
5.4.2.3 Biodistribution and Gene Expression 134
5.5 Viral Vectors 136
5.5.1 rAAV: Properties 136
5.5.2 rAAV Serotype and Biodistribution 138
5.6 Summary 139
5.7 References 139
Part III: Challenges and Opportunities
6 Bioanalytical Methods Used for Pharmacokinetic Evaluations
of Biotech Macromolecule Drugs: Issues, Assay Approaches,
and Limitations 147
Jean W. Lee
6.1 Introduction 147
6.2 Bioanalytical Methods for Macromolecule Drug Analysis: Common
Considerations 148
6.2.1 Sample Integrity and Analyte Stability 148
6.2.2 Surface Adsorption 149
6.2.3 Process of Method Development and Validation of Bioanalytical
Methods for Macromolecule Drug Analysis 150
6.2.4 Reference Standards 151
6.2.5 Drug Compounds that Exist Endogenously 152
6.2.6 Validation Samples, Quality Controls, and Assay Range 353
6.2.7 Protein Binding Problems 153
6.3 The Bioanalytical Method Workhorses 154
6.3.1 Ligand Binding Assays: Immunoassays 157
6.3.1.1 Common Method Approach 157
6.3.1.2 Advantages of Immunoassays 158
6.3.1.3 Issues and Limitations of Immunoassays 158
6.3.2 HPLC ESI MS/MS Methods 162
i.ontents I X
6.3.2.1 Common Method Approach 162
6.3.2.2 AdvantagesofHPLC ESI MS/MSMethods 162
6.3.2.3 Issuesand Limitations of LC ESI MS/MS Methods 262
6.4 Case Studies 267
6.4.1 Development and Validation of an ELISA Method for an Antibody
Drug 167
6.4.2 Development and Validation of a Sandwich Immunoradiometric
Method Using Commercial Kits for a Recombinant Peptide Drug 169
6.4.3 Development and Validation of LC MS/MS Method for a Peptide
Drug 171
6.5 Future Perspectives: Emerging Quantitative Methods 173
6.5.1 Sample Clean Up 173
6.5.2 Innovations in MS Instruments 173
6.5.3 Quantification using Signature Hydrolytic Peptides 174
6.5.4 Advances in Ligand Reagents Design and Production 175
6.6 Conclusions 175
6.7 References 176
7 Limitations of Noncompartmental Pharmacokinetic Analysis
of Biotech Drugs 281
Arthur B. Straughn
7.1 Introduction 181
7.2 The Conceptof Volume of Distribution 282
7.3 Calculation of Vss 283
7.4 Pitfalls in Calculating Vss 285
7.5 Results and Discussion 187
7.6 Conclusions 288
7.7 References 188
8 Bioequivalence of Biologics 289
Jeffrey S. Barrett
8.1 Introduction 289
8.2 Prevailing Opinion: Science, Economics, and Politics 191
8.3 Biologics: Time Course of Immunogenicity 293
8.4 Pharmaceutical Equivalence 296
8.4.1 How Changes in Quality Might Affect Safety and Efficacy 197
8.5 Bioequivalence: Metrics and Methods for Biologics? 298
8.6 Case Study: Low Molecular Weight Heparins 200
8.7 Conclusions 205
8.8 References 206
9 Biopharmaceutical Challenges: Pulmonary Delivery of Proteins
and Peptides 209
Kun Cheng and Ram I. Mahato
9.1 Introduction 209
9.2 Structure and Physiology of the Pulmonary System 211
9.2.1 Airway Epithelium 212
9.2.2 Alveolar Epithelium 214
9.3 Barriers to Pulmonary Absorption of Peptides and Proteins 214
9.4 Strategies for Pulmonary Delivery 215
9.4.1 Intratracheal Instillation 215
9.4.2 Aerosol Inhalation 215
9.4.2.1 Aerosol Deposition Mechanisms 216
9.4.2.2 Devices for Pulmonary Drag Delivery 216
9.5 Experimental Models 220
9.5.1 Isolated Perfused Lung Model 220
9.5.2 Cell Culture Models 220
9.6 Pulmonary Delivery of Peptides and Proteins 221
9.6.1 Mechanisms of Peptide Absorption after Pulmonary Delivery 221
9.6.2 Mechanisms of Protein Absorption after Pulmonary Delivery 222
9.6.3 Pulmonary Delivery of Peptides and Proteins 223
9.6.3.1 Insulin 223
9.6.3.2 Salmon Calcitonin 227
9.6.3.3 Luteinizing Hormone Releasing Hormone (LHRH) Agonists/
Antagonists 229
9.6.3.4 Vasopressin 230
9.6.3.5 Granulocyte Colony Stimulating Factor (G CSF) 231
9.6.3.6 Interferons 232
9.6.3.7 TSH, FSH, and HCG 233
9.6.3.8 Ekstase Inhibitors 233
9.7 Limitations of Aerosol Delivery 234
9.8 Summary 235
9.9 References 235
10 Biopharmaceutical Challenges: Delivery of Oligonucleotides 243
Lloyd C. Tillman and Gregory E. Hardee
10.1 Introduction 243
10.2 ASOs: The Physico Chemical Properties 244
10.3 Local Administration 246
10.3.1 Ocular Delivery 246
10.3.2 Local Gastrointestinal Delivery 247
10.3.2.1 Rectal Dosing 247
10.3.2.2 Oral Dosing 248
10.3.3 Pulmonary Delivery 249
10.3.3.1 Formulation Considerations 251
Contents I )0
10.3.3.2 Deposition and Uptake 251
10.3.4 Delivery to the Brain 253
10.3.5 Topical Delivery 253
10.3.6 Other Local Delivery Approaches 254
10.4 Systemic Delivery 255
10.4.1 Parenteral Routes 255
10.4.1.1 Sustained Release Subcutaneous Formulations 256
10.4.2 Oral Delivery 257
10.4.2.1 Permeability 258
10.4.2.2 Systemic Bioavailability 260
10.5 Conclusions 265
10.6 References 266
11 Custom Tailored Pharmacokinetics and Pharmacodynamics
via Chemical Modifications of Biotech Drugs 271
Francesco M. Veronese and Paolo Caliceti
11.1 Introduction 271
11.2 Polymers Used in Biotechnological Drug PEGylation 272
11.3 Advantages of PEG as Drug Carrier 273
11.4 Chemical Aspects Critical for the Pharmacokinetics of Drug
Conjugates 274
11.5 Insulin 279
11.6 Interferons 282
11.7 Avidin 285
11.8 Non Peptide Drug Conjugation 288
11.8.1 Amphotericin B 289
11.8.2 Camptothecins 290
11.8.3 Cytosine Arabinoside (Ara C) 292
11.9 Concluding Remarks 292
11.10 References 292
12 Exposure Response Relationships for Therapeutic Biologie
Products 295
Mohammad Tabrizi and Lorin K. Roskos
12.1 Introduction 295
12.2 Overview of Pharmacokinetics and Pharmacodynamics 295
12.2.1 Pharmacokinetics 295
12.2.1.1 Absorption 296
12.2.1.2 Distribution 296
12.2.1.3 Elimination 296
12.2.1.4 Immunogenicity 298
12.2.2 Pharmacodynamics 298
12.3 Hormones 300
12.3.1 Insulin 301
12.3.2 Parathyroid Hormone 302
12.4 Cytokines 303
12.4.1 Interleukin 2 305
12.5 Growth Factors 306
12.5.1 Epoetin oc 307
12.6 Soluble Receptors 308
12.6.1 Etanercept 308
12.7 Monoclonal Antibodies (mAbs) 310
12.7.1 Therapeutic Antibodies in Inflammatory Diseases 311
12.7.1.1 Anti TNF a Antibodies 314
12.7.1.2 Efalizumab 316
12.7.1.3 Omalizumab 317
12.7.2 Therapeutic Antibodies in Oncology 317
12.7.2.1 Rituximab 318
12.7.2.2 Bevacizumab 319
12.7.2.3 Trastuzumab 320
12.8 Conclusions 321
12.9 References 321
Part IV: Examples for the Integration of Pharmacokinetic and
Pharmacodynamic Concepts Into the Biotech Drug Development Plan
13 Preclinical and Clinical Drug Development of Tasidotin,
a Depsi Pentapeptide Oncolytic Agent 331
Peter L. Bonate, Larry Arthaud, and Katherme Stephenson
13.1 Introduction 331
13.2 The Dolastatins 331
13.3 Discovery and Preclinical Pharmacokinetics of Tasidotin 333
13.4 Preclinical Pharmacology of Tasidotin and ILX651 C Carboxylate 334
13.5 Toxicology of Tasidotin 334
13.6 Clinical Pharmacology and Studies of Tasidotin in Patients with Solid
Tumors 335
13.7 Clinical Pharmacology of ILX651 C Carboxylate 341
13.8 Exposure Response Relationships 342
13.9 Discussion 343
13.10 Summary 349
13.11 References 349
Contents IXV
14 Clinical Drug Development ofCetuximab, a Monoclonal Antibody 353
Arno Nolting, Floyd E. Fox, and Andreas Kovar
14.1 Introduction 353
14.2 Specific Considerations in Oncologic Drug Development 354
14.3 Introduction to the Clinical Pharmacokinetics ofCetuximab 356
14.4 Early Attempts to Characterize the PK ofCetuximab 356
14.5 PK ofCetuximab Following Poolingof Data Across All Studies 357
14.5.1 Comparison of Single Dose PK Parameters at Various Dose Levels 357
14.5.1.1 Maximum Serum Concentration 357
14.5.1.2 Area Under the Concentration Time Curve 359
14.5.1.3 Clearance 360
14.5.1.4 Elimination Half Life 361
14.5.1.5 Volume of Distribution 361
14.5.2 Drug Metabolism and in vitro Drug Drug Interaction Studies 362
14.5.3 Comparison of Single and Multiple Dose PK at the Approved Dosing
Regimen 362
14.6 Characterization ofCetuximab PK by a Population PK Approach 364
14.7 Drug Drug Interaction Studies 366
14.8 Conclusions 369
14.9 References 370
15 Integration of Pharmacokinetics and Pharmacodynamics Into the Drug
Development of Pegfilgrastim, a Pegylated Protein 373
Bing Bing Yang
15.1 Introduction 373
15.2 Overviewof Filgrastim Pharmacokinetics 374
15.3 The Making of Pegfilgrastim 3 75
15.4 Preclinical Pharmacokinetics and Pharmacodynamics of
Pegfilgrastim 376
15.5 Pharmacokinetic and Pharmacodynamic Modeling 379
15.6 Clinical Pharmacokinetics and Pharmacodynamics of
Pegfilgrastim 381
15.7 Basis for the Fixed Dose Rationale 385
15.8 Clinical Evaluation of the Fixed Dose 389
15.9 Summary 391
15.10 References 391
Subject Index 395 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author_GND | (DE-588)114901619 |
| building | Verbundindex |
| bvnumber | BV022446743 |
| callnumber-first | R - Medicine |
| callnumber-label | RS380 |
| callnumber-raw | RS380 |
| callnumber-search | RS380 |
| callnumber-sort | RS 3380 |
| callnumber-subject | RS - Pharmacy |
| classification_rvk | VX 8550 |
| classification_tum | CIT 840f |
| ctrlnum | (OCoLC)427472250 (DE-599)BVBBV022446743 |
| dewey-full | 615.19 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.19 |
| dewey-search | 615.19 |
| dewey-sort | 3615.19 |
| dewey-tens | 610 - Medicine and health |
| discipline | Chemie / Pharmazie Chemie-Ingenieurwesen Medizin |
| discipline_str_mv | Chemie / Pharmazie Chemie-Ingenieurwesen Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02000nam a2200493 c 4500</leader><controlfield tag="001">BV022446743</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20090304 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">070531s2006 ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783527314089</subfield><subfield code="c">Gb. : EUR 139.00</subfield><subfield code="9">978-3-527-31408-9</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3527314083</subfield><subfield code="c">Gb. : EUR 139.00</subfield><subfield code="9">3-527-31408-3</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)427472250</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV022446743</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield><subfield code="a">DE-20</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-M49</subfield><subfield code="a">DE-29T</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RS380</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.19</subfield><subfield code="2">22</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VX 8550</subfield><subfield code="0">(DE-625)147830:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">CIT 840f</subfield><subfield code="2">stub</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmacokinetics and pharmacodynamics of biotech drugs</subfield><subfield code="b">principles and case studies in drug development</subfield><subfield code="c">ed. by Bernd Meibohm</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Weinheim</subfield><subfield code="b">Wiley-VCH</subfield><subfield code="c">2006</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XXI, 403 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biotecnología farmaceútica</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Desarrollo de drogas</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drogas - Efectos fisiológicos</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Farmacocinética</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelentwicklung</subfield><subfield code="0">(DE-588)4143176-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakodynamik</subfield><subfield code="0">(DE-588)4174134-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakokinetik</subfield><subfield code="0">(DE-588)4115557-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Pharmakokinetik</subfield><subfield code="0">(DE-588)4115557-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Arzneimittelentwicklung</subfield><subfield code="0">(DE-588)4143176-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Pharmakodynamik</subfield><subfield code="0">(DE-588)4174134-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Arzneimittelentwicklung</subfield><subfield code="0">(DE-588)4143176-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="C">b</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Meibohm, Bernd</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)114901619</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015654691&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-015654691</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV022446743 |
| illustrated | Illustrated |
| index_date | 2024-07-02T17:34:47Z |
| indexdate | 2024-07-09T20:57:46Z |
| institution | BVB |
| isbn | 9783527314089 3527314083 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-015654691 |
| oclc_num | 427472250 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM DE-20 DE-29 DE-M49 DE-BY-TUM DE-29T |
| owner_facet | DE-19 DE-BY-UBM DE-20 DE-29 DE-M49 DE-BY-TUM DE-29T |
| physical | XXI, 403 S. Ill., graph. Darst. |
| publishDate | 2006 |
| publishDateSearch | 2006 |
| publishDateSort | 2006 |
| publisher | Wiley-VCH |
| record_format | marc |
| spelling | Pharmacokinetics and pharmacodynamics of biotech drugs principles and case studies in drug development ed. by Bernd Meibohm Weinheim Wiley-VCH 2006 XXI, 403 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Biotecnología farmaceútica Desarrollo de drogas Drogas - Efectos fisiológicos Farmacocinética Arzneimittelentwicklung (DE-588)4143176-5 gnd rswk-swf Pharmakodynamik (DE-588)4174134-1 gnd rswk-swf Pharmakokinetik (DE-588)4115557-9 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Pharmakokinetik (DE-588)4115557-9 s Arzneimittelentwicklung (DE-588)4143176-5 s DE-604 Pharmakodynamik (DE-588)4174134-1 s b DE-604 Meibohm, Bernd Sonstige (DE-588)114901619 oth HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015654691&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Pharmacokinetics and pharmacodynamics of biotech drugs principles and case studies in drug development Biotecnología farmaceútica Desarrollo de drogas Drogas - Efectos fisiológicos Farmacocinética Arzneimittelentwicklung (DE-588)4143176-5 gnd Pharmakodynamik (DE-588)4174134-1 gnd Pharmakokinetik (DE-588)4115557-9 gnd |
| subject_GND | (DE-588)4143176-5 (DE-588)4174134-1 (DE-588)4115557-9 (DE-588)4143413-4 |
| title | Pharmacokinetics and pharmacodynamics of biotech drugs principles and case studies in drug development |
| title_auth | Pharmacokinetics and pharmacodynamics of biotech drugs principles and case studies in drug development |
| title_exact_search | Pharmacokinetics and pharmacodynamics of biotech drugs principles and case studies in drug development |
| title_exact_search_txtP | Pharmacokinetics and pharmacodynamics of biotech drugs principles and case studies in drug development |
| title_full | Pharmacokinetics and pharmacodynamics of biotech drugs principles and case studies in drug development ed. by Bernd Meibohm |
| title_fullStr | Pharmacokinetics and pharmacodynamics of biotech drugs principles and case studies in drug development ed. by Bernd Meibohm |
| title_full_unstemmed | Pharmacokinetics and pharmacodynamics of biotech drugs principles and case studies in drug development ed. by Bernd Meibohm |
| title_short | Pharmacokinetics and pharmacodynamics of biotech drugs |
| title_sort | pharmacokinetics and pharmacodynamics of biotech drugs principles and case studies in drug development |
| title_sub | principles and case studies in drug development |
| topic | Biotecnología farmaceútica Desarrollo de drogas Drogas - Efectos fisiológicos Farmacocinética Arzneimittelentwicklung (DE-588)4143176-5 gnd Pharmakodynamik (DE-588)4174134-1 gnd Pharmakokinetik (DE-588)4115557-9 gnd |
| topic_facet | Biotecnología farmaceútica Desarrollo de drogas Drogas - Efectos fisiológicos Farmacocinética Arzneimittelentwicklung Pharmakodynamik Pharmakokinetik Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015654691&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT meibohmbernd pharmacokineticsandpharmacodynamicsofbiotechdrugsprinciplesandcasestudiesindrugdevelopment |